Cosmo Pharmaceuticals Statistics

Total Valuation

Cosmo Pharmaceuticals has a market cap or net worth of GBP 938.90 million. The enterprise value is 831.21 million.

Market Cap	938.90M
Enterprise Value	831.21M

Important Dates

The next estimated earnings date is Thursday, March 6, 2025.

Earnings Date	Mar 6, 2025
Ex-Dividend Date	Jul 10, 2024

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.77%
Shares Change (QoQ)	+0.54%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	8.42M

Valuation Ratios

The trailing PE ratio is 15.92.

PE Ratio	15.92
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	11.08
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.59, with an EV/FCF ratio of 8.60.

EV / Earnings	14.09
EV / Sales	5.21
EV / EBITDA	9.59
EV / EBIT	11.22
EV / FCF	8.60

Financial Position

The company has a current ratio of 4.85, with a Debt / Equity ratio of 0.00.

Current Ratio	4.85
Quick Ratio	4.35
Debt / Equity	0.00
Debt / EBITDA	0.01
Debt / FCF	0.01
Interest Coverage	21.40

Financial Efficiency

Return on equity (ROE) is 14.80% and return on invested capital (ROIC) is 9.59%.

Return on Equity (ROE)	14.80%
Return on Assets (ROA)	7.82%
Return on Capital (ROIC)	9.59%
Revenue Per Employee	463,565
Profits Per Employee	173,998
Employee Count	325
Asset Turnover	0.27
Inventory Turnover	3.19

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +8.09% in the last 52 weeks. The beta is 1.29, so Cosmo Pharmaceuticals's price volatility has been higher than the market average.

Beta (5Y)	1.29
52-Week Price Change	+8.09%
50-Day Moving Average	63.13
200-Day Moving Average	70.54
Relative Strength Index (RSI)	60.37
Average Volume (20 Days)	479

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cosmo Pharmaceuticals had revenue of GBP 157.15 million and earned 58.99 million in profits. Earnings per share was 3.66.

Revenue	157.15M
Gross Profit	120.17M
Operating Income	72.89M
Pretax Income	73.43M
Net Income	58.99M
EBITDA	84.71M
EBIT	72.89M
Earnings Per Share (EPS)	3.66

Full Income Statement

Balance Sheet

The company has 113.11 million in cash and 1.23 million in debt, giving a net cash position of 111.88 million.

Cash & Cash Equivalents	113.11M
Total Debt	1.23M
Net Cash	111.88M
Net Cash Per Share	n/a
Equity (Book Value)	428.48M
Book Value Per Share	26.34
Working Capital	123.54M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 99.47 million and capital expenditures -2.83 million, giving a free cash flow of 96.64 million.

Operating Cash Flow	99.47M
Capital Expenditures	-2.83M
Free Cash Flow	96.64M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 76.47%, with operating and profit margins of 46.38% and 37.53%.

Gross Margin	76.47%
Operating Margin	46.38%
Pretax Margin	46.72%
Profit Margin	37.53%
EBITDA Margin	53.90%
EBIT Margin	46.38%
FCF Margin	61.50%

Dividends & Yields

This stock pays an annual dividend of 1.68, which amounts to a dividend yield of 2.57%.

Dividend Per Share	1.68
Dividend Yield	2.57%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	2
Payout Ratio	6.07%
Buyback Yield	0.77%
Shareholder Yield	0.77%
Earnings Yield	6.28%
FCF Yield	10.29%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Cosmo Pharmaceuticals has an Altman Z-Score of 5.97.

Altman Z-Score	5.97
Piotroski F-Score	n/a